• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Hodges Michael R.

    7/25/24 4:11:11 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TBIO alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Hodges Michael R.

    (Last) (First) (Middle)
    C/O TELESIS BIO INC.
    10431 WATERIDGE CIRCLE, SUITE 150

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/16/2024
    3. Issuer Name and Ticker or Trading Symbol
    Telesis Bio Inc. [ TBIO ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Rob Cutler, Attorney-in-Fact 07/25/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TBIO

    DatePrice TargetRatingAnalyst
    8/4/2021$45.00 → $38.00Neutral
    Roth Capital
    8/3/2021$19.00 → $38.00Market Perform
    SVB Leerink
    8/3/2021Outperform → Market Perform
    William Blair
    7/26/2021$28.00 → $45.00Buy
    Roth Capital
    More analyst ratings

    $TBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Krueger Todd was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:07:04 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Golub Steven J was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:06:35 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Hlavinka Sarah E. was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:06:03 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

      Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to the Company of up to approximately $21 million. The Company's recently launched proprietary next-generation enzymatic synthesis platform, Gibson SOLA™, allows customers to take full control of their nucleic acid supply-chain,

      3/18/25 9:00:00 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

      SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications. The collaboration integrates Telesis Bio's Gibson

      9/25/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

      SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO) ("Telesis" or the "Company"), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, announced today that it has notified the Nasdaq Stock Market LLC ("Nasdaq") of its decision to delist the Company's shares of common stock, par value $0.001 per share (the "Common Stock") and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Telesis intends to file a Form 25 with the Securities and Exchange Commission (the "SEC")

      9/10/24 4:30:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Translate Bio with a new price target

      Roth Capital reiterated coverage of Translate Bio with a rating of Neutral and set a new price target of $38.00 from $45.00 previously

      8/4/21 10:08:32 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVB Leerink reiterated coverage on Translate Bio with a new price target

      SVB Leerink reiterated coverage of Translate Bio with a rating of Market Perform and set a new price target of $38.00 from $19.00 previously

      8/3/21 11:37:09 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Translate Bio downgraded by William Blair

      William Blair downgraded Translate Bio from Outperform to Market Perform

      8/3/21 11:20:22 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Telesis Bio Inc.

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      11/8/24 8:23:25 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

      SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

      11/6/24 4:50:27 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

      SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

      11/6/24 4:05:27 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

      SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024. Highlights Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high-fidelity long DNA and mRNA on a variety of liquid handling platforms. The Company's presentation "Enhancing Therapeutic Protein Production with Gibson SOLA Enzymatic DNA Assembly: Pioneeri

      8/7/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Telesis Bio Appoints William J. Kullback Chief Financial Officer

      SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. "Bill's deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to help lead us through the next phase of the Company's growth," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. "We are thrilled to welcome Bill to our team and excited to have another lead

      8/29/23 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Telesis Bio Inc.

      15-12G - Telesis Bio Inc. (0001850079) (Filer)

      1/14/25 4:35:26 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Telesis Bio Inc.

      EFFECT - Telesis Bio Inc. (0001850079) (Filer)

      1/7/25 12:15:02 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Telesis Bio Inc.

      EFFECT - Telesis Bio Inc. (0001850079) (Filer)

      1/7/25 12:15:03 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Financials

    Live finance-specific insights

    See more
    • Telesis Bio Reports First Quarter 2024 Financial Results

      SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024.  In discussing results, recently appointed President and CEO Eric Esser said, "I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA offerings continue to gain traction and are delivering real improvements in speed and simplicity to our customers in their discovery workflows. I'm also excited abo

      5/9/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

      SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, "I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin aga

      3/28/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports Third Quarter 2023 Financial Results

      SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. "This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened board of directors and management team: Appointed Greg Herrema, Senior Advisor to Novalis LifeSciences to the Telesis Bio board of directors in October 2023. Mr. Herrema's distinguished car

      11/13/23 4:22:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials